BOSTON SCIENTIFIC CORPORATION (NYSE:BSX) Files An 8-K Regulation FD DisclosureITEM 7.01.
REGULATION FD DISCLOSURE.
On July 24, 2018, we issued a press release recommending that our stockholders reject an unsolicited “mini-tender” offer by TRC Capital Corporation (“TRC”) to purchase up to threemillion shares of our common stock, constituting up to 0.217% of the outstanding shares of our common stock. A copy of the press release is being furnished as Exhibit99.1 to this Current Report on Form 8-K.
This information, including Exhibit 99.1, will not be deemed “filed” for any purpose, including for the purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section and it will not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
|
ITEM 9.01. |
FINANCIAL STATEMENTS AND EXHIBITS. |
(d) The following exhibit is being furnished with this Current Report on Form 8-K.
|
Exhibit No. |
Description |
|
99.1 |
Press Release issued by Boston Scientific Corporation dated July 24, 2018 |
BOSTON SCIENTIFIC CORP ExhibitEX-99.1 2 ss101158_ex9901.htm NEWS RELEASE Exhibit 99.1 Boston Scientific Corporation Recommends Stockholders Reject ‘Mini-Tender’ Offer by TRC Capital Corporation MARLBOROUGH,…To view the full exhibit click here
About BOSTON SCIENTIFIC CORPORATION (NYSE:BSX)
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and PI businesses. Its Rhythm Management segment consists of CRM and EP businesses. Its MedSurg segment consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its interventional cardiology products include Drug-Eluting Coronary Stent Systems, Core Coronary Technology, Intravascular Imaging and Structural Heart Therapy. Its peripheral products include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters.
